Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
24 Luglio 2023 - 2:00PM
Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company
dedicated to advancing health equity and outcomes through the
delivery of accurate infectious disease testing in the moment of
need, at the point of care, today announced that it received
written notice (the “Notice”) from The Nasdaq Stock Market LLC
(“Nasdaq”) dated July 20, 2023, that the Company has regained
compliance with the minimum bid price requirement of at least $1.00
per share under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid
Price Requirement”). In order to regain compliance, the Company’s
common stock was required to maintain a closing bid price of at
least $1.00 per share for a minimum of ten consecutive business
days which the Company satisfied on July 19, 2023. Accordingly, the
Notice stated that Nasdaq now considers the matter closed.
The Notice follows the Company’s 1-for-15 reverse stock split
approved by stockholders on June 9, 2023, and effected at 5:00 p.m.
Eastern time on July 5, 2023, after which the Company’s common
stock closed at a minimum of $1.00 per share for the 10 consecutive
business days ended July 19, 2023.
About Talis BiomedicalTalis Biomedical is
dedicated to advancing health equity and outcomes through the
delivery of accurate infectious disease testing in the moment of
need, at the point of care. The Company plans to develop and
commercialize innovative products on its sample-to-answer Talis
One® system to enable accurate, low cost, and rapid molecular
testing. For more information, visit talisbio.com.
Forward-Looking Statements This press release
may contain forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Words such as
“may,” “might,” “will,” “would,” “should,” “believe,” “expect,”
“anticipate,” “could,” “estimate,” “continue,” “predict,”
“potential,” “forecast,” “project,” “plan,” “intend” or similar
expressions, or other words that convey uncertainty of future
events or outcomes can be used to identify these forward-looking
statements. Forward-looking statements include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the Company’s
compliance with the minimum required for continued listing on The
Nasdaq Capital Market. These statements are not guarantees of
future performance and are subject to certain risks, uncertainties
and other factors that could cause actual results and events to
differ materially and adversely from those indicated by such
forward-looking statements including, among others, the Company’s
ability to maintain compliance with the per share bid price
requirement for continued listing on The Nasdaq Capital Market,
market conditions and their impact on the trading price of our
common stock and other risks and uncertainties that are described
more fully in the “Risk Factors” section and elsewhere in our
filings with the Securities and Exchange Commission and available
at www.sec.gov, including in our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. These statements are based upon
information available to us as of the date of this press release,
and while we believe such information forms a reasonable basis for
such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently
uncertain and investors are cautioned not to unduly rely upon these
statements. Any forward-looking statements that we make in this
announcement speak only as of the date of this press release, and
Talis Bio assumes no obligation to update forward-looking
statements whether as a result of new information, future events or
otherwise after the date of this press release, except as required
under applicable law.Contact Media &
InvestorsEmily Faucetteefaucette@talisbio.com415-595-9407
Grafico Azioni Talis Biomedical (NASDAQ:TLIS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Talis Biomedical (NASDAQ:TLIS)
Storico
Da Set 2023 a Set 2024